“…miR‐490 was found to be downregulated in different cancer types and its functional analysis, wherever reported, identified its role majorly as a tumor‐suppressive miRNA (Table 1). Interestingly, the extent of its downregulation has been correlated with increased tumor progression of acute myeloid leukemia (C. Wang et al, 2020), bladder cancer (Han et al, 2011; Lan et al, 2015; Li et al, 2013; Wei et al, 2016; L. Wu et al, 2019; Xiang et al, 2019; Zhang, Wang, et al, 2019), breast cancer (Fan et al, 2020; Jia et al, 2016; Tao et al, 2018; Zhao & Zheng, 2016), cholangiocarcinoma (Leng et al, 2019), colorectal cancer (Hamfjord et al, 2012; Liu et al, 2018; X. Xu et al, 2015; Zheng et al, 2016), digestive cancers (Tang et al, 2016), endometrial cancer (Shao et al, 2018; Sun et al, 2015), esophageal squamous cell carcinoma (Kang et al, 2018; Li & Zang, 2019; Pan et al, 2019; Zabihula et al, 2019), Ewing's sarcoma (Nakatani et al, 2012), gastric cancer (Luo & Liang, 2020; Qu et al, 2017; Shen et al, 2015; Zhang, Ma, et al, 2019; Zhou et al, 2016), glioblastoma (Giunti et al, 2019; Vinchure et al, 2019; F. Zhang et al, 2019; Zhao et al, 2018), hepatocellular carcinoma (Cai et al, 2018; Chen et al, 2017, 2019; Dai et al, 2019; Ding et al, 2020; Dou et al, 2017; Fang et al, 2018; Li et al, 2018; Wang et al, 2018; Wojcicka et al, 2014; Xu et al, 2017, 2018; Yu et al, 2019; H. Zhang et al, 2020; Zheng et al, 2018), lung cancer (Dong et al, 2020; Gu et al,…”